JPMorgan Chase & Co. Has $53,000 Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB)

JPMorgan Chase & Co. increased its position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 5,137.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,509 shares of the biopharmaceutical company’s stock after acquiring an additional 3,442 shares during the period. JPMorgan Chase & Co.’s holdings in Assembly Biosciences were worth $53,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Technologies LLC boosted its position in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 15,451 shares in the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Insider Buying and Selling

In related news, Director Michael Houghton purchased 3,202 shares of Assembly Biosciences stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by insiders.

Assembly Biosciences Price Performance

Shares of NASDAQ ASMB opened at $13.80 on Tuesday. Assembly Biosciences, Inc. has a twelve month low of $9.84 and a twelve month high of $19.93. The firm has a fifty day simple moving average of $15.48 and a 200 day simple moving average of $15.75.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.